Passage Bio Inc. (PASG) Next Earnings Date & Expected ±12.5% Move

PASG scores 34 out of 100 with a letter grade of E, labeled "Roarable Strong Sell — Forensic Risk / Avoid." The five pillars are:

• Fundamental Cash Engine: 8 / 20. Per the RQD rating, this reflects ROIC of -35% and an FCF yield of 0%. The SEC financials show net losses in each reported period, so the cash engine is currently not generating returns on capital.
• Whale 13F Flow: 3 / 20. Per the RQD rating, this pillar covers institutional accumulation and options positioning. It is the lowest-scoring pillar and points to weak institutional support.
• Insider Conviction: 5 / 20. Per the RQD rating, this pillar covers SEC Form 4 and Congressional PTR cluster flow.
• Macro Regime Fit: 8 / 20. Per the RQD rating, beta is 1.0 with a sector-sensitivity read. The score signals limited alignment with the prevailing regime.
• Forensic Balance Sheet: 10 / 20. Per the RQD rating, Altman Z is 2.5, Piotroski F is 3/9, and Debt/Equity is 0.5. This is the highest-scoring pillar but still sits in the lower half.

For a prospective investor evaluating the stock today, these pillars indicate that the upside case rests on a cash-consuming biotech with no reported revenue, negative ROIC, and weak institutional and insider signals. The balance-sheet pillar offers some support, but the cash-engine and flow pillars weigh the overall score down. Any valuation discussion must be weighed against the absence of earnings, the very small market capitalization, and the lack of analyst coverage.

Passage Bio Inc. Is a NASDAQ-listed issuer in the Health Care sector, operating in the Biotechnology: Biological Products (No Diagnostic Substances) industry..

The company reported operating losses and net losses in each period, with operating income of -$49.3M in FY 2025 narrowing from -$70.4M in FY 2024 and -$108.4M in FY 2023. Gross, operating, and net margins are each 0% per the market data, consistent with zero reported revenue. Per the market data, ROIC is -35%. The Altman Z-Score is 2.5 and the Piotroski F-Score is 3/9, both . Per the RQD rating, Debt/Equity is 0.5, while the SEC financials report debt as N/A for each period.

• 🐂 Primary Bull Case: Balance-sheet pillar scores 10/20 with Altman Z of 2.5 and reported cash of $46.3M in FY 2025, offering some near-term liquidity cushion. With Fundamental Cash Engine at 8/20 (ROIC -35.0%, FCF yield —) and Institutional Whale Flow at 3/20, sustained execution supports upside toward the top of the $3.29 – $20.00 52-week range.
• 🐻 Primary Bear Case: Zero reported revenue, net losses of -$45.5M in FY 2025, ROIC of -35%, and a whale-flow pillar of 3/20 signal a cash-consuming issuer with weak institutional support. Investors must weigh current valuation against — operating margins and a 1.00 macro beta if sector demand softens.

The sector is Health Care and the industry is Biotechnology: Biological Products (No Diagnostic Substances). Upstream and downstream dependencies, sector correlations beyond beta of 1. The merger-vote timing noted in the news feed is the only near-term event a prospective investor could track against the company's cash position.

• Key Question #1: What are the terms, counterparty, and deal price of the merger referenced in the news feed, and what happens to PASG shareholders if the November 5 vote passes?
• Key Question #2: How long does the reported cash of $46.3M fund operations at the FY 2025 net loss rate of -$45.5M?
• Key Question #3: What is the reported share count, and how does it reconcile with the $11.3M market capitalization and $3.52 price?